Comparator Issues Thwart Cosentyx Benefit Assessment In Germany
Executive Summary
A key trial comparing Novartis’s Cosentyx with etanercept did not allow a fair comparison of the two products because it failed to ensure all patients received adequate medical care, said IQWiG, Germany’s HTA body.